Real world experience with pazopanib in patients with advanced/metastatic kidney cancer
Results from the PRINCIPAL study to evaluate the real world [...]
An overview of the management of rare subtypes of kidney cancer
This interview with Dr Ramaprasad Srinivasan from the National Cancer Institute in [...]
Adjuvant therapy with TKIs has no benefit for high-risk kidney cancer
According to the results of a recent meta-analysis of three [...]
CARMENA trial results show that many people with advanced kidney cancer do not need surgery
The results from CARMENA, a randomised phase III clinical trial [...]
Personalised approach to the management of kidney cancer
This article summarises a presentation by Dr Ulka Vaishampayanon at [...]
Patient-reported outcomes show improved quality of life with the nivolumab-ipilimumab combination
Patient-reported outcomes data from the Phase 3 CheckMate-214 trial of [...]
European Commission approves cabozantinib for first-line kidney cancer
The European Commission has approved cabozantinib (Cabometyx) for the first-line [...]
Results from a major study might lead to reduced animal testing by pharmaceutical companies
A major, groundbreaking study carried out by Elsevier, a global [...]
Cabozantinib significantly improves overall survival in people with previously treated advanced kidney cancer
Cabozantinib significantly improves overall survival in previously treated patients with [...]
NHS to cut clinical trial bureaucracy to improve access to cutting-edge therapies
The NHS has introduced new processes to fast track research [...]
